Back to search results

Observational Study on Glucose Tolerance in Cirrhosis Patients After Liver Transplant

This observational study aims to understand why some adults with cirrhosis (severe liver scarring) who don't have diabetes develop high blood sugar or diabetes after a liver transplant. Researchers will look at various tests, including lab work, body measurements, imaging, and advanced monitoring like continuous glucose monitors (devices that track blood sugar levels) and wrist actigraphs (devices that track activity and sleep). You would wear these devices and have oral glucose tolerance tests (which measure how your body processes sugar) both before and after your liver transplant. The goal is to identify risk factors for developing diabetes after transplant. The study plans to enroll 60 participants.

Study design
This is an observational study with no specified phase, planning to enroll 60 participants. It involves collecting data through various tests and monitoring devices.
What's involved
You would periodically wear a continuous glucose monitor and wrist actigraph, and undergo oral glucose tolerance tests before and after your liver transplant. These tests, along with body composition measurements, will be done every three months until and after transplant.
Compensation
Not stated in the trial record.
Follow-up
Your care will be followed electronically for up to five years after your liver transplant to assess outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06950788

Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

Recruiting
Not specifiedAges 18–75Observational
University of Chicago
~60 participants
Updated 2026-05-07 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Early post-transplant hyperglycemia
Measured over 45 days after transplant
+1 more outcome measured

Conditions

Cirrhosis, Liver
Diabetes Mellitus Risk
Transplant; Failure, Liver
Transplant-Related Disorder

Explore related trials

CirrhosisLiver Transplantation

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Alan L Hutchison, MD PhD · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

Alan L Hutchison, MD PhD
[email protected]
773-702-1000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients presenting to liver transplant clinic with a diagnosis of cirrhosis.
Age \>18 yrs.
Ability to understand and sign written consent form, or have a legally-authorized representative or proxy who can be approached for consent

Exclusion

Patients without consent
Patients with implantable cardioverter defibrillator devices or automated implantable cardioverter defibrillator devices will be excluded from the bio-electrical impedance analysis portion of the measurements.
Patients with unremovable electrical medical devices or devices that cannot turn off will be excluded from the bio-electrical impedance analysis measurements
Pregnant patients
Incarcerated patients
Patients with a history of type 2 diabetes mellitus diagnosed \> 5 years ago will be excluded from the Oral Glucose Tolerance Test portion of the study

What this trial measures

  • Early post-transplant hyperglycemia45 days after transplant

    Blood sugars above 200 mg/dL or requiring insulin therapy

  • Post-transplant diabetes45 days to 365 days after liver transplant

    Hemoglobin A1c \> 6.5% or two-hour glucose from an oral glucose tolerance test ≥ 200 mg/dL after liver transplant